Tests GnRH therapy on thinking skills in people with Down syndrome
Tests pulsed GnRH, a hormone, against a saline dummy in people with Down syndrome.
Key facts
- Who runs it
- Nelly Pitteloud
- Where
- Lausanne, SwitzerlandSee the site
- Trial code
- Registry title
- GnRH Therapy on Cognition in Down Syndrome
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 56 people, planned
- Started
- 27 Aug 2020
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- GnRH, gonadorelin acetate
- 0.9% NaCl
- Record updated
- 12 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers and adults with Down syndrome (trisomy 21) who can follow the study procedures. It tests a hormone pump (GnRH) against a placebo pump.
- Age
- 16 to 50 years
- Sex
- Women and men can join.
- Disease stage
- Diagnosis of trisomy 21 (Down syndrome).
- Earlier treatment
- People cannot be taking medicines that change hormones, such as spironolactone, ketoconazole, anticoagulants, corticosteroids, ACTH hormone, or psychotropic drugs.
Main reasons for not taking part
- Acute illness
- Chronic alcohol abuse, illicit drug use or anabolic steroid abuse
- Known pituitary adenoma or other hormone-dependent tumours
- Women with ovarian cysts, non-hypothalamic anovulation, pregnancy or breastfeeding
- Cannot have an MRI scan (for example a pacemaker or metal clips)
This trial only enrols participants with Down syndrome. The registry sentence this rests on: Diagnosis of trisomy 21
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Diagnosis of trisomy 21
- Verbal expression (ability to follow the procedures of the study)
- Consent to a non-hormonal contraception during the whole duration of the study For women: intra-uterine device with copper, a prior tubal ligation or condoms for the partner For men: condoms or vasectomy
Who cannot take part
- Chronic alcohol abuse, illicit drug use, anabolic steroid abuse, psychotropic drugs reported by caregivers
- Taking medication that modifies hormones: spironolactone, ketoconazole, anticoagulants, corticosteroids, ACTH hormone, psychotropics, including antidepressants, antipsychotics and anticonvulsants
- Acute illness (clinical or biochemical findings suggesting acute illness/hospitalization)
- Females: ovarian cysts, non-hypothalamic anovulation (i.e. polycystic ovary syndrome), pregnancy or lactation
- Known pituitary adenoma and other hormone-dependent tumours
- Participation in another clinical study
- Intention to become a parent during the course of the study
- Males: hematocrit > 54%
- Contraindications for MRI (e.g. pacemaker, metal clips,etc)
- Participant or his/her legal representative do not want to be informed in case of incidental findings
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 50 years old?
Where in Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandContact: Pulse-UP StudyTaking people
About the trial
What the trial wants to find out
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood.
Read full original descriptionShow less
To date, there is no treatment available for the cognitive or olfactory defects in DS. The development of an effective treatment targeting cognitive dysfunction in DS adolescents/adults would be warranted.
GnRH, a decapeptide secreted by hypothalamic neurons is the pilot light of reproduction in all mammals. Pulsatile GnRH acts on the gonadotrophs via the GnRH receptor (GNRHR) in the pituitary gland to stimulate LH and FSH, which themselves will act on the gonads to produce gametes and steroids. However, GNRHR are also expressed in cerebral cortex, hippocampus, amygdala, habenula, olfactory structures, and adrenal gland, suggesting that GnRH may have a role beyond reproduction.
Recently, GnRH has been shown to be involved in the process of ageing and lifespan control. Notably, in murine models, GnRH acts as an anti-ageing factor, independent of sex hormones. While ageing is characterized by hypothalamic inflammation and diminished neurogenesis, particularly in the hypothalamus and the hippocampus, GnRH was able to promote adult neurogenesis.
The regulation of GnRH secretion is complex and involves hormonal, neuronal input, and environmental factors.
Prévot et al. recently explored cognition within the Ts65Dn model and showed an age-dependent loss of the ability to recognize new objects. Also, these mice exhibit defects in olfaction. Given the role of GnRH in anti-aging mice model, pulsatile GnRH or continuous GnRH infusion (leading to desensitization of the GNRHR) were given to the Ts65Dn mice for two weeks. Amazingly, pulsatile but not continuous GnRH therapy was able to recover cognitive and olfaction defects.
The 2 groups in the trial
- Pulsatile GnRH pump treatmentExisting treatment, for comparison
Treatment: GnRH, gonadorelin acetate
- Pulsatile placebo pump treatmentPlacebo, for comparison
Treatment: 0.9% NaCl
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control Study
- Plain-language title
- Tests GnRH therapy on thinking skills in people with Down syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04390646, who can take part
- Record updated
- 12 February 2024